Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for familial adenomatous polyposis
NL-OMON55226Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of guselkumab in Colonic Adenomatous Polyposis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage change from baseline in rectal/pouch polyp burden at Week 24. Started Dec 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on NL-OMON55226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55226.